Developed in collaboration with Genentech, BI-204 is a monoclonal antibody targeting oxidised forms of low-density lipoprotein cholesterol.
In the randomized placebo controlled double-blind multicenter Phase IIa study, BI-204 is delivered intravenously to 144 patients with stable atherosclerotic vascular disease.
The trial is designed to demonstrate a reduction in inflammation at the site of the inflamed atherosclerotic plaque as quantified by FDG-PET imaging at weeks four and 12.
BioInvent president and CEO Svein Mathisen said they hope to show that BI-204 is bringing the treatment of atherosclerosis and acute coronary syndromes one step forward.
The company plans to report top-line data from the study in Q3, 2012.